Collegeville, Pennsylvania (ots/PRNewswire) – The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), today adopted a positive opinion recommending to grant a marketing authorization for CONBRIZA(TM) (bazedoxifene) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. CONBRIZA, an investigational medicine, is in [...]
Tag Archive > Treatment Option
VELCADE(R) (bortezomib) Findings Reinforce Efficacy and Survival Across Multiple Patient Populations
Beerse, Belgium (ots/PRNewswire) – – Preliminary Phase II Re-treatment Results and two new Analyses From Phase III VISTA Presented at ASH Annual Meeting Janssen-Cilag today announced preliminary results from a prospective, international, multicenter, open-label, phase II study showing re-treatment with VELCADE(R) (bortezomib) is an effective and well-tolerated treatment option for patients with relapsed multiple myeloma [...]
